Role of allotransplantation in older patients with AML

In this issue of Blood, Sorror et al1 present data showing no benefit of allogeneic hematopoietic cell transplantation (HCT) in older and medically infirm patients with acute myeloid leukemia (AML). In their large prospective multi-institutional observational study, they not only looked at the influence of age, comorbidities, genetic risk, and remission status on outcome but also paid special attention to frailty, impaired quality of life, depression, and diminished functional status.

Automated summary

In this study, Sorror et al demonstrate that allogeneic hematopoietic cell transplantation does not provide any benefits for older and medically infirm patients with acute myeloid leukemia.